Percutaneous coronary intervention in octogenarians and the safety of glycoprotein IIb/IIIa inhibitors

Journal of the American College of Cardiology

Volumn 42, Issue 3, 2003, Pages 433-436

  Ragosta, Michael ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COMORBIDITY; CORONARY ARTERY DISEASE; CORONARY ARTERY SURGERY; DRUG SAFETY; GERIATRICS; HUMAN; NOTE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVASCULARIZATION; RISK; SURVIVAL; TREATMENT OUTCOME;

EID: 0043129030     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00652-1     Document Type: Editorial

References (15)

1. Mark Twain. Following the Equator. Hartford, Connecticut: American Publishing Co., 1897.
2. Administration on Aging: Aging into the 21st century. Demographic changes. Available at: www.aoa.dhhs.gov/aoa/stats/aging21/demography.html. Accessed on February 28, 2003.
3. Weintraub WS, Veledar E, Thompson T, Burnette J, Jurkovitz C, Mahoney E. Percutaneous coronary intervention outcomes in octogenarians during the stent era (National Cardiovascular Network). Am J Cardiol 2001;88:1407-10.
4. Klein LW, Block P, Brindis RG, et al., and the ACC-NCDR Registry. Percutaneous coronary interventions in octogenarians in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol 2002;40:394-402.
5. Graham MM, Ghali WA, Faris PD, et al., for the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) Investigators. Survival after coronary revascularization in the elderly. Circulation 2002;105:2378-84.
6. Pfisterer M, the TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. Lancet 2001;358:951-7.
7. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
8. The IMPACT II Investigators. Randomised placebo controlled trial of eptifibatide on complications of percutaneous coronary interventions: IMPACT II. Lancet 1997;349:1422-8.
9. EPILOG Trial Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
10. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
11. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
12. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-43.
13. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo controlled trial. Lancet 2000;356:2037-44.
14. Karvouni E, Katritisis DG, Ioannidis JPA. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32.
15. Sadeghi HM, Grines CL, Chandra HR, et al. Percutaneous coronary interventions in octogenarians: glycoprotein IIb/IIIa receptor inhibitors' safety profile. J Am Coll Cardiol 2003;42:428-32.